Product Currently Expected to Generate $10-15M in Additional Revenues
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
and consumer care products to improve men’s and women’s health and
respiratory diseases, today announced that it has officially launched
FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal
steroid active pharmaceutical ingredient (“API”) and form for nasal
allergy relief over the last 7 years. The Company is launching
FlutiCare™ in over 10,000 independent pharmacies, direct and through
Amerisource Bergen and McKesson, via its Beyond Human® extensive print
media platform and through its extensive online channels and
distributors, including its own website, Amazon, and Walmart online
stores. As a second phase of its launch, Innovus Pharma will launch
FlutiCare™ to large retail stores.
FlutiCare™ will be available OTC with the same prescription strength and
same delivery method as Flonase®* and ClariSpray®*. The Company
currently believes that FlutiCare™ will be the most affordable
fluticasone propionate nasal spray on the market and is now available in
one dose, a 30 Day (120 Sprays) treatment and is the only one providing
an monthly autoship plan.
“We are very excited to launch FlutiCare™ OTC and provide all patients
with allergy relief,” stated Dr. Bassam Damaj, President and Chief
Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the
most prescribed Rx 24-hour nasal allergy spray API and form in the U.S.
over the past 7 years by a factor of over 10 to 1,” he continued.
FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”)
for OTC availability through Innovus Pharma’s partner’s approved
abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy
relief joins the growing Innovus Pharma product family, offering a
burgeoning portfolio of non-prescription medicine and consumer care
supplements to consumers.
FlutiCare™ becomes the Company’s second available allergy relief product
along with AllerVarx™, a patented dietary supplement formulated to
provide relief during the allergy season, already on the market.
In addition, the Company, pending FDA’s guidance, plans to move forward
with a fluticasone kit for nasal allergy containing FlutiCare™ and our
upcoming saline nasal spray NasaVa™.
FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone
propionate (“USP”) per spray, a nasal corticosteroid that provides
24-hour temporary relief of seasonal and perennial nasal allergy
symptoms. FlutiCare™ can be used to relieve both indoor and outdoor
nasal allergy symptoms caused by pollen, dust, animal dander, and other
indoor and outdoor allergens. Nasal allergy symptoms include, nasal
congestion, runny nose, sneezing, itchy nose, etc.
FlutiCare™ contains the nasal steroid API that is physician recommended
and consumer preferred
- #1 form used by patients;
- #1 nasal steroid active prescribed by physicians;
- Familiar to patients, comfort of a known & trusted medicine;
- Engrained in patients’ allergy management; and
- Effective and safe.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products, men’s and
women’s health supplements, related diagnostics and medical devices. The
Company is actively pursuing opportunities where existing prescription
drugs have recently, or are expected to, change from prescription (or
Rx) to OTC, as well as related products.
For more information, go to www.innovuspharma.com;
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the FlutiCare™ product in the United States
if approved in that country, estimated market for its products, and
statements about achieving its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.
*Flonase® is a registered trademark of GSK and ClariSpray® is a
registered trademark of Bayer.